Yanni & Associates Investment Advisors LLC Purchases Shares of 10,900 Bristol Myers Squibb Company $BMY

Yanni & Associates Investment Advisors LLC bought a new position in Bristol Myers Squibb Company (NYSE:BMY) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 10,900 shares of the biopharmaceutical company’s stock, valued at approximately $588,000. Bristol Myers Squibb accounts for 0.6% of Yanni & Associates Investment Advisors LLC’s investment portfolio, making the stock its 23rd biggest position.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Entrust Financial LLC purchased a new position in shares of Bristol Myers Squibb in the 4th quarter worth approximately $47,000. Intrua Financial LLC boosted its holdings in shares of Bristol Myers Squibb by 9.3% in the 4th quarter. Intrua Financial LLC now owns 21,070 shares of the biopharmaceutical company’s stock worth $1,137,000 after purchasing an additional 1,788 shares during the period. Peak Asset Management LLC boosted its holdings in shares of Bristol Myers Squibb by 1.5% in the 4th quarter. Peak Asset Management LLC now owns 33,397 shares of the biopharmaceutical company’s stock worth $1,801,000 after purchasing an additional 500 shares during the period. TD Private Client Wealth LLC boosted its holdings in shares of Bristol Myers Squibb by 2.7% in the 4th quarter. TD Private Client Wealth LLC now owns 27,829 shares of the biopharmaceutical company’s stock worth $1,501,000 after purchasing an additional 725 shares during the period. Finally, CMG Global Holdings LLC purchased a new position in shares of Bristol Myers Squibb in the 4th quarter worth approximately $223,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Price Performance

Shares of BMY stock opened at $57.30 on Tuesday. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. The firm has a market capitalization of $117.02 billion, a P/E ratio of 16.10, a P/E/G ratio of 0.16 and a beta of 0.26. The stock has a 50 day moving average price of $58.57 and a 200 day moving average price of $55.53.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. The business had revenue of $11.49 billion during the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.Bristol Myers Squibb’s revenue was up 2.6% on a year-over-year basis. During the same period in the previous year, the company posted $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, sell-side analysts predict that Bristol Myers Squibb Company will post 6.31 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd were given a dividend of $0.63 per share. The ex-dividend date of this dividend was Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.4%. Bristol Myers Squibb’s payout ratio is 70.79%.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on BMY. Barclays assumed coverage on Bristol Myers Squibb in a report on Thursday, February 19th. They issued an “overweight” rating and a $75.00 target price for the company. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Sunday, April 19th. Weiss Ratings reissued a “hold (c)” rating on shares of Bristol Myers Squibb in a research note on Monday, March 23rd. Wells Fargo & Company reissued an “outperform” rating and set a $60.00 price target (up from $55.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Finally, UBS Group reissued a “buy” rating and set a $70.00 price target on shares of Bristol Myers Squibb in a research note on Friday, March 6th. Eight investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $61.31.

Insiders Place Their Bets

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the sale, the executive vice president directly owned 159,248 shares of the company’s stock, valued at $9,820,824.16. The trade was a 15.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.05% of the stock is currently owned by company insiders.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.